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Background: Active renin mass concentration (ARC) is independent of the endogenous 
level of angiotensinogen, and less variable and more reproducible than plasma renin activity. 
Reference values for the aldosterone-to-renin ratio (ARR) using ARC are still undefined. The 
objective of the present study was to determine the threshold of ARR using ARC measurement 
to screen for primary aldosteronism.
Methods: A total of 211 subjects were included in the study, comprising 78 healthy 
  normotensive controls, 95 patients with essential hypertension, and 38 patients with confirmed 
primary aldosteronism (20 with surgery-confirmed aldosterone-producing adenoma and 18 
with idiopathic adrenal hyperplasia). Blood samples were drawn from ambulatory patients 
and volunteers in the mid-morning without specific dietary restriction for measuring plasma 
aldosterone concentration, ARC, and serum potassium.
Results: Most normotensive controls and essential hypertension patients had ARR results below 
100 pmol/ng, a value which corresponded to 3.3 times the median of these two groups.
Conclusion: Patients with ARR values above this level should be considered for further 
investigation (confirmatory tests) or for repeat testing should ARR values be borderline. This 
study indicates that ARC can be used reliably in determining ARR for primary aldosteronism 
screening.
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Introduction
Primary aldosteronism, as initially described by Conn,1 is defined as an   inappropriate 
and autonomous production of aldosterone by the adrenal glands. With improved 
screening approaches, such as the ratio of plasma aldosterone to renin levels (ARR), 
the average number of screened patients with primary aldosteronism has increased 
considerably.2–6 Plasma renin activity has been usually measured to define ARR.7–9 
More recently, the use of active renin mass concentration (ARC), instead of the plasma 
renin activity assay, has gained broader acceptance.10 Indeed, ARC does not require ice 
cooling of the specimen, is independent of the endogenous level of   angiotensinogen, is 
easier to standardize, and is more reproducible than plasma renin activity. In addition, 
studies have demonstrated a significant correlation between plasma renin activity and 
ARC measurements,11–14 although this correlation is weaker at low renin levels7 but 
improved under captopril stimulation.14 So far, only a few small studies have reported an 
ARR threshold using ARC measurements in screening for primary aldosteronism.15–18 
The objective of the present study was to assess the value of ARC in determining ARR 
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Methods and materials
Blood samples for measuring plasma aldosterone concen-
tration, ARC, and serum potassium were drawn according 
to the Endocrine Society Clinical Practice Guideline19 
from ambulatory patients and volunteers in the mid-
morning at the outpatient clinic of the L’Hôtel-Dieu de 
Québec   Hospital, a tertiary care center. Informed consent 
was obtained for all subjects, as required by the local 
ethics committee. Preliminary data for the current study 
has been reported previously.20 The control group was 
recruited from normotensive subjects (blood pressure below 
140/90 mmHg) coming for routine blood samples. Patients 
with a history of hypertension, diabetes, or with cardiac, 
hepatic, or renal diseases were excluded. Hypertensive 
patients had the same blood samples drawn while being 
investigated for hypertension. Patients were diagnosed with 
essential hypertension when clinical and laboratory inves-
tigation excluded any secondary forms of hypertension. 
Among patients referred to us for sustained hypertension 
and hypokalemia, those with primary aldosteronism were 
included retrospectively in the analysis. The ARR using 
plasma renin activity or ARC was not measured prior to 
referral. Our initial investigation of these patients showed 
that they had low ARC, high plasma aldosterone concen-
trations, and increased ARR values. A definite diagnosis 
of primary aldosteronism was confirmed in all patients by 
demonstrating an inappropriate autonomous hypersecre-
tion of aldosterone with captopril suppression and salt 
loading procedures as described previously.21   Subtyping 
investigations included computed tomography imaging 
with fine cuts (2.5–3.0 mm) and a postural stimulation test 
in all patients.22 Adrenal venous sampling (10 patients) 
and/or adrenal scintigraphy using 6 beta 131-iodomethyl-
19-norcholesterol after dexamethasone suppression (six 
patients) were performed in patients with conflicting results. 
Beta-blockers, clonidine, renin-angiotensin blockers, and 
thiazide diuretics were withdrawn progressively one week 
prior to the investigation. Spironolactone was discontinued 
six weeks prior to blood sampling. Postsynaptic α1 blockers 
and calcium channel blockers were maintained or added 
when necessary to control hypertension. No subject in any 
of the three groups was taking oral contraceptive pills.
Blood was collected in EDTA tubes for ARC and plasma 
aldosterone measurement, maintained at room temperature 
during delivery to the laboratory, and rapidly frozen at −20°C 
after centrifugation. Plasma ARC was determined using a 
two-site immunometric assay (Renin III Generation, Cisbio 
Bioassays, Bedford, MA). Typical imprecision in the normal 
range for this assay shows coefficients of variation below 4% 
within-run and below 7.5% between-run. Reference values 
ranged from 7 ng/L to 25 ng/L in the recumbent position and 
from 12 ng/L to 43 ng/L after ambulation. Plasma aldosterone 
concentration was measured by radioimmunoassay accord-
ing to the manufacturer’s recommendations (DSL-8600 kit, 
Beckman Coulter, Fullerton, CA). Typical imprecision in the 
normal range for this assay shows coefficients of variation 
below 7% within-run and below 10% between-run.   Reference 
values with patients in the recumbent position ranged from 
90 pmol/L to 290 pmol/L and after normal ambulation from 
290 pmol/L to 871 pmol/L. Serum potassium was deter-
mined using an autoanalyzer system (Ilab 1800 or Beckman 
LX-20).
statistical analysis
Results are expressed as mean ± standard error of the mean. 
The unpaired Student’s t-test was used to establish statistically 
significant differences between groups. Two approaches were 
tested to establish cutoff values and to assess sensitivity and 
specificity; the first one was based on laboratory reference 
values (upper limit for aldosterone and lower limit for renin) 
and the second one corresponded to the optimal discriminator 
from receiver-operating characteristic (ROC) curves (point 
closest to the upper left corner). For ARR, we used the 95th 
percentile for the controls and essential hypertension patients. 
Table 1 Clinical and biochemical data
Control subjects Essential hypertension Primary aldosteronism
Number of subjects 78 95 38
gender (F/M) 35/43 56/39 13/25
Age (years, mean ± sD) 36 ± 13 51 ± 12 53 ± 11
serum K (mmol/L) 4.2 ± 0.03 (4.2) 4.1 ± 0.06 (4.2) 3.2 ± 0.07a (3.2)
Plasma aldosterone (pmol/L) 382 ± 28 (320) 339 ± 25 (272) 928 ± 116a (664)
ARC (ng/L) 11.3 ± 0.8 (10) 19.7 ± 2.9 (9) 2.3 ± 0.2a (2)
Aldosterone/ARC ratio (pmol/ng) 42.4 ± 3.3 (32) 37.8 ± 2.9 (27) 519 ± 99a (278)
Notes: aP , 0.01 versus control subjects and essential hypertension. Mean ± standard error of the mean. The median value for serum K, plasma aldosterone, ARC, and 
aldosterone/ARC ratio appears in brackets. 
Abbreviation: ARC, active renin mass concentration.International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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Table 2 Comparison of cutoff values derived from the upper limits of laboratory references or 95th percentile values and those from 
the receiver-operator characteristic curve
Cutoff values Sens/spec. (%) Sens + spec-1 (%) Accuracy (%)a Kappa test
Aldo ULR 871 pmol/L 34/95 29 84 0.36
ROC 480 pmol/L 79/77 56 78 0.43
ARC ULR 7 ng/dL 100/67 67 78 0.43
ROC 4.3 ng/dL 100/85 85 88 0.67
ARR 95th percentile 101 pmol/ng 100/95 95 96 0.92
ROC 130 pmol/ng 100/100 100 100 1.0
Note: aP , 0.001 for all values. Control and essential hypertension populations were pooled to calculate specificity; the median for ARR is 30.6 with a 95th percentile of 
101 (3.3-fold the median).
Abbreviations: Aldo, plasma aldosterone concentration; ARC, active renin mass concentration; ARR, aldosterone-renin ratio; ROC, receiver-operator characteristic curve; 
ULR, upper limit of laboratory reference values; Sens/spec, sensitivity/specificity.
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Figure 1 Individual values of plasma aldosterone, active renin mass concentration 
(ARC) and aldosterone to renin ratio (ARR) in the three groups.
ROC curves were generated and their surfaces evaluated using 
the Mann–Whitney U test. For the ROC curves, controls and 
essential hypertension results were pooled to assess specific-
ity. Statistical assessments of proportions were done using 
the χ2 test and Cohen’s kappa test.
Results
A total of 211 subjects were included in the study, comprising 
78 healthy normotensive controls, 95 patients with essential 
hypertension, and 38 patients with confirmed primary aldos-
teronism (20 had surgery-confirmed unique aldosterone-
producing adenoma and 18 were presumed to have idiopathic 
adrenal hyperplasia). Table 1 presents the patient characteris-
tics and basal biochemical determinations. The mean age of 
control subjects was lower but not significantly different from 
the other two patient groups. Plasma   aldosterone and ARR 
values were significantly higher (P , 0.01), and ARC and 
serum potassium values were significantly lower (P , 0.01) 
in primary aldosteronism patients. Mean ARR values were not 
significantly different in patients with unique adenoma and 
with idiopathic adrenal hyperplasia (614 ± 169 pmol/ng versus 
414 ± 91 pmol/ng, P . 0.05). Figure 1 depicts individual val-
ues for plasma aldosterone, ARC, and ARR from the subjects 
in all three groups. ARR values (bottom graph) discriminate 
better between the primary aldosteronism patients, essential 
hypertension patients, and control subjects. Table 2 shows 
comparisons between the two approaches used to establish cut-
off values in screening for primary aldosteronism (upper and 
lower limits of laboratory references or 95th percentile values 
and ROC curve analysis). The results show that the ROC curve 
analysis has the best sensitivity and specificity in establishing 
cutoff values for ARR. Figure 2 shows ROC curves for plasma 
aldosterone concentration, ARC, and ARR. ARR values above 
130 pmol/ng detected primary aldosteronism with a sensitivity 
and specificity of 100%. Table 3 provides the area under the 
ROC curves ± standard error of the mean and 95% confidence 
intervals.International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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Table 4 suggested screening thresholds for aldosterone-to-renin 
ratio using active renin mass concentration (pmol/ng)
#100 essential hypertension
100–130 gray zone (repeat)
$130 Primary aldosteronisma
Note: aCombined with plasma aldosterone concentration . 416 pmol/L.
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Figure 2 Analysis of receiver-operating characteristic curves. Circle, plasma aldosterone; 
triangle, active renin mass concentration; square, aldosterone to renin ratio.
There were significant correlations between serum potas-
sium and ARR (r = −333, P , 0.001), and ARC (r = +0.304, 
P , 0.001) and aldosterone (r = −0.274, P = 0.007). All but 
three patients with essential hypertension had an ARR below 
100 pmol/ng (106, 102, 126 pmol/ng; range 2–126 pmol/ng). 
When repeated, the ratio value of 126 pmol/ng decreased to 
56 pmol/ng. All primary aldosteronism patients had ARR 
values above 130 pmol/ng (range 137–3349 pmol/ng). The 
mean ARR in normotensive subjects was 42.4 ± 3.3 pmol/ng 
(range 2–118); five subjects were above 100 pmol/ng (104, 
103, 104, 105, and 118 pmol/ng). Table 4 shows suggested 
screening thresholds for ARR.
Discussion
In the present study, which included control subjects 
and patients with essential hypertension and primary 
aldosteronism, we used ARC to define ARR in screening for 
primary aldosteronism. Patients with essential hypertension 
and control subjects had similar mean ARR values (mostly 
Table 3 Area under the receiver-operator characteristic curve ± 
standard error of the mean and confidence intervals
Area under  
curve
± SEM Confidence 
interval (95%)
Aldo (pmol/L) 0.86a,b 0.032 0.79–0.91
ARC (ng/L) 0.96c 0.012 0.93–0.98
Aldo/ARC ratio  
(pmol/ng)
1.0 0.002 0.95–1.00
Notes: aP , 0.01 versus ARC; bP , 0.001 versus aldo/ARC ratio; cP , 0.01 versus 
aldo/ARC ratio. 
Abbreviations: Aldo, plasma aldosterone concentration; ARC, active renin mass 
concentration; seM, standard error of the mean.
below 100 pmol/ng). ARR results above 130 pmol/ng indi-
cated primary aldosteronism with a sensitivity and specificity 
of 100%. ARR results that fall between 100 pmol/ng and 
130 pmol/ng (gray zone) suggest a need for repeat testing.
So far, few laboratories have attempted to establish refer-
ence values for ARR by using ARC expressed as pmol/ng. 
In a group of 36 hypertensive patients (nine with adrenal 
adenoma), Ferrari et al12 reported that an ARR $ 150 pmol/ng 
can indicate primary aldosteronism. Perschel et al16 measured 
ARR in 76 healthy normotensive volunteers and 28 primary 
aldosteronism patients. No patients with essential hyper-
tension were included in that study. Their proposed cutoff 
value for ARR in normotensive volunteers versus primary 
aldosteronism patients was 118 pmol/ng. The cutoff value 
adopted by Westerdahl et al18 to separate essential hyperten-
sion was 100 pmol/ng.
To our knowledge, the current report is the largest study 
in this area, and included control subjects, essential hyperten-
sives, and primary aldosteronism patients. We compared two 
approaches to establish the cutoff values for plasma aldosterone, 
ARC and ARR (Table 2). The ROC curve analysis was clearly 
the best performing test, and ARR showed the highest sensitivity 
and specificity in detecting primary aldosteronism.
The combination of an ARR cutoff value with a plasma 
aldosterone threshold (.416 pmol/L or .15 ng/dL) has been 
suggested by some investigators.8 This approach limits the 
number of false positive ARR, namely in patients with low 
renin essential hypertension, which represents around 25% of 
essential hypertension. However, to this end, it is important 
to use ambulatory plasma aldosterone values. Indeed, many 
patients with idiopathic adrenal hyperplasia exhibit normal 
early-morning plasma aldosterone values in the recumbent 
position, but their plasma aldosterone concentrations increase 
markedly with ambulation.22
As for many screening tests performed without rigorous 
conditions throughout daily routine blood samplings, we 
observed borderline ARR results overlapping the proposed 
cutoff values. For this reason, we introduced the notion of a 
“gray zone” to help clinicians sort out patients in whom ARR 
should be repeated. In such cases, more attention should be 
paid to sampling conditions, ie, dietary sodium intake and 
serum potassium concentration, with careful revision and International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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adjustment of medication. In addition, it is important to point 
out that the thresholds reported in the current paper cannot 
be applied universally, and should be adapted to each labora-
tory depending on the assays utilized. To this end, the median 
values (see Table 1) can be used as comparison points; for 
instance, the proposed ARR threshold for control subjects 
and essential hypertension (100 pmol/ng) corresponds to 
3.3 times the median value of these two groups.
The use of the ARR appears to be the preferred screening 
approach for distinguishing between patients with essential 
hypertension and those with primary aldosteronism.10,23 
In past years, the ARR was based almost exclusively 
on plasma renin activity measurements. More recently, 
the utilization of ARC, instead of plasma renin activity, 
has gained acceptance. Indeed, studies have revealed a 
significant correlation between ARC and plasma renin 
activity assays.11–14 Moreover, the immunometric method 
to measure ARC offers many advantages over the plasma 
renin activity procedure. These advantages include this 
method being easier to standardize than the enzymatic 
assay, which can be altered by variation in the concentra-
tion of the endogenous angiotensinogen, having a better 
interlaboratory and intralaboratory coefficient of variation 
and reproducibility that allows comparisons between dif-
ferent laboratories,24 and angiotensin II being more closely 
correlated with immunoreactive renin than with plasma 
renin activity.25,26 Recent methods have improved the 
sensitivity of the assay, which can now be used to assess 
suppressed renin levels.27 Because of these advantages, 
ARC is progressively becoming the preferred method for 
measuring renin in humans. A recent study by Wu et al17 
showed that ARC is as accurate as plasma renin activity 
when using the captopril suppression confirmatory test. 
In conclusion, this study indicates that ARC can be used 
reliably to determine ARR when screening for primary 
aldosteronism. Patients with essential hypertension usually 
have ARR values # 100 pmol/ng, while ARR in patients 
with primary aldosteronism is $130 pmol/ng. Results that 
fall between 100 and 130 pmol/ng (gray zone) suggest a 
need for repeat testing.
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